EUROPEAN JOURNAL OF BIOMEDICAL AND PHARMACEUTICAL SCIENCES
http://www.ejbps.com

ISSN 2349-8870
Coden USA: EJBPBO
Volume: 13
Issue: 7
Year: 2026

TRANSDERMAL DRUG DELIVERY SYSTEMS: A COMPREHENSIVE REVIEW

B. Premkumar*, D. Dhachinamoorthi, C. Santosh

Department of Pharmaceutics & Biotechnology, Sree Abirami College of Pharmacy, Eachanari, Coimbatore - 641 021, Tamil Nadu, India. [Affiliated to The Tamil Nadu Dr. M. G. R. Medical University, Chennai]

***Corresponding Author: B. Premkumar**

Department of Pharmaceutics & Biotechnology, Sree Abirami College of Pharmacy, Eachanari, Coimbatore - 641 021, Tamil Nadu, India. [Affiliated to The Tamil Nadu Dr. M. G. R. Medical University, Chennai].

DOI: https://doi.org/10.5281/zenodo.21292959

How to cite this Article: B. Premkumar*, D. Dhachinamoorthi, C. Santosh. (2026). Transdermal Drug Delivery Systems: A Comprehensive Review. European Journal of Biomedical and Pharmaceutical Sciences, 13(7), 463–472.

Article Received on 15/06/2026 **Article Revised on 05/07/2026** **Article Published on 10/07/2026**

ABSTRACT

Transdermal Drug Delivery Systems (TDDS) represent one of the most significant advances in non-invasive drug delivery technology, offering a reliable and patient-friendly alternative to oral and parenteral routes of administration. The skin, being the largest organ of the human body, serves as both a portal and a formidable barrier to drug permeation. A thorough understanding of the multilayered structure of human skin—particularly the stratum corneum and its lipid-bilayer organization—is fundamental to the rational design of effective transdermal formulations. This review comprehensively addresses the anatomy and physiology of skin and its associated barriers to drug permeation; the diverse categories of penetration enhancers including chemical, physical, and biochemical approaches; the classification, design principles, and mechanisms of various transdermal drug delivery systems; and the formulation strategies and in vitro/in vivo evaluation methodologies employed in transdermal product development. Emphasis is placed on clinically relevant drug candidates, polymer selection, adhesive systems, and modern analytical techniques used to characterize transdermal patches. The future potential of nanotechnology-based transdermal systems, microneedle arrays, and iontophoretic devices is also briefly addressed.

KEYWORDS: Transdermal Drug Delivery, Skin Barrier, Stratum Corneum, Penetration Enhancers, Transdermal Patch, Iontophoresis, Microneedles, Flux, Permeability Coefficient, Controlled Release.

INTRODUCTION

The administration of drugs through the skin for systemic therapeutic effects has attracted enormous scientific interest over the past four decades. Transdermal Drug Delivery Systems (TDDS) are specialized dosage forms designed to deliver therapeutically effective amounts of drug across the skin barrier and into the systemic circulation, thereby bypassing hepatic first-pass metabolism, avoiding gastrointestinal degradation, and providing a non-invasive, controlled-release platform with enhanced patient compliance. Since the regulatory approval of the first transdermal scopolamine patch (Transderm-Scōp) by the U.S. FDA in 1979, the field has grown substantially to encompass drugs ranging from cardiovascular agents and hormones to analgesics, antidepressants, and nicotine replacement therapies.The unique appeal of transdermal delivery lies in its ability to maintain steady-state plasma drug concentrations over extended periods (12–168 hours), thereby reducing the frequency of dosing and the peaks and troughs characteristic of oral and injectable formulations. As described by Chien (1992), an ideal TDDS should deliver the drug at a predetermined, controlled rate; maintain a constant plasma concentration within the therapeutic window; allow for easy application and removal by the patient; and cause minimal skin irritation or sensitization. These objectives are governed by the physicochemical properties of the drug molecule, the composition and design of the transdermal formulation, and the structure and permeability characteristics of the skin.

The skin serves a dual function in the context of TDDS—it is simultaneously the target tissue for topical delivery and the primary barrier to systemic drug absorption. The stratum corneum, the outermost and most impermeable layer of the epidermis, composed of dead, flattened corneocytes embedded in a lipid-rich

extracellular matrix, represents the principal rate-limiting barrier to the permeation of most drug molecules. Overcoming this formidable barrier while maintaining skin integrity and biocompatibility is the central challenge of transdermal drug delivery research.

This review systematically examines the structural and functional barriers of human skin, the various categories and mechanisms of penetration enhancers, the classification and design of transdermal drug delivery systems, and the established methodologies for their formulation and evaluation. The review draws on foundational textbooks by Chien (1992), Robinson and Lee (1992), Jain (1997), Vyas and Khar (2002), and the Encyclopedia of Controlled Delivery (Mathiowitz), as well as contemporary publications in the Indian Journal of Pharmaceutical Sciences, Journal of Controlled Release, and Drug Development and Industrial Pharmacy.

Structure of Skin and Barriers to Drug Permeation



Cross-Sectional Structure of Human Skin Showing Layers and Barrier Zones Relevant to Transdermal Drug Delivery The skin is the largest organ of the human body, covering a surface area of approximately 1.7–2.0 m² in adults and accounting for about 16% of total body weight. It performs multiple critical physiological functions including thermoregulation, sensory perception, immune surveillance, and protection against mechanical, chemical, microbial, and ultraviolet radiation insults. From the perspective of transdermal drug delivery, the structural organization of the skin—illustrated in Fig. 1—is the primary determinant of drug permeation kinetics and the key design parameter for transdermal formulations.

Stratum Corneum – The Primary Barrier

The stratum corneum (SC) is the outermost layer of the epidermis, comprising 15–20 layers of non-viable, flattened, anucleate corneocytes (dead keratinocytes) embedded within a continuous extracellular matrix of multilamellar lipid bilayers. The corneocytes are elongated, protein-dense cells (~25–35 µm in diameter) containing a highly organized network of keratin filaments, filaggrin cross-links, and cornified cell envelope proteins. The extracellular lipid matrix—comprising ceramides (40%), cholesterol (25%), free fatty acids (25%), and smaller amounts of cholesterol esters and sphingolipids—forms a tortuous, hydrophobic pathway that severely restricts the paracellular diffusion of hydrophilic drugs and macromolecules. The "brick and mortar" model of the SC, proposed by Elias (1983) and described by Vyas and Khar (2002), conceptualizes the corneocytes as bricks and the intercellular lipid lamellae as mortar. Drugs traversing the SC must navigate this tortuous path, traveling approximately 500 times the thickness of the SC (~10–20 µm) due to the tortuous diffusion route around corneocytes. The SC has a water content of 15–25% under normal conditions; reduction in this hydration reduces drug diffusivity, while hydration enhancement—achieved by occlusive patches—improves drug permeation.

Viable Epidermis

Below the stratum corneum lies the viable epidermis (VE), a living cellular layer approximately 50–100 µm thick comprising four sublayers: the stratum granulosum, stratum spinosum, stratum basale, and—in palmar and plantar skin—the stratum lucidum. The keratinocytes of the viable epidermis undergo continuous proliferation at the basal layer and progressive differentiation as they migrate toward the skin surface over a 2–3 week turnover cycle. The viable epidermis represents a secondary barrier, primarily through its aqueous environment (water

content ~80%) which limits the permeation of lipophilic drugs that are highly soluble in the SC lipids. Enzymatic metabolism of drugs within the viable epidermis—catalyzed by cytochrome P450 enzymes, esterases, and sulfotransferases—constitutes an additional pharmacokinetic barrier.

Dermis

The dermis, spanning 1,000–4,000 µm in thickness, is a highly vascularized connective tissue layer composed of collagen and elastin fibers interspersed in a hydrophilic proteoglycan ground substance. It houses the cutaneous microvascular network, lymphatic vessels, sensory nerve endings, hair follicles, sebaceous glands, and eccrine sweat glands. The dermal microcirculation represents the pharmacokinetic sink for transdermally delivered drugs—once a drug penetrates through the SC and viable epidermis, it is rapidly absorbed into the dermal capillaries and enters the systemic circulation. The blood flow rate through the dermis (~0.05 mL/min per cm^2 in resting skin) significantly exceeds the flux of most transdermal drug systems, ensuring that the dermis does not constitute a significant diffusion barrier under normal physiological conditions.

Routes of Transdermal Permeation

Drugs traverse the skin via three principal routes: (1) Transcellular (intracellular) pathway—direct diffusion through corneocytes and intercellular lipids, predominated by small hydrophilic molecules;
(2) Intercellular (extracellular) pathway—diffusion through the continuous lipid bilayer between corneocytes, the predominant route for lipophilic drugs; and (3) Appendageal (shunt) pathway—diffusion through hair follicles, sebaceous glands, and sweat ducts, bypassing the SC. The appendageal route, although representing only 0.1–1% of the skin surface area, provides a rapid onset pathway particularly important for ions, macromolecules, and nanoparticles that cannot efficiently traverse the intact SC. Studies published in Drug Development and Industrial Pharmacy have established that under steady-state permeation conditions, the intercellular lipid pathway contributes over 90% of total transdermal drug flux for most small organic molecules with log P values between 1 and 3.

Barriers to Transdermal Drug Delivery

- **Physicochemical Barriers:** The stratum corneum's lipid bilayer acts as the primary physicochemical barrier. The lipid matrix restricts the permeation of highly hydrophilic drugs (log P < 1) while allowing reasonable passage of lipophilic molecules. Conversely, drugs with log P > 4 exhibit excessive partitioning into the SC lipids and fail to partition adequately into the aqueous viable epidermis, resulting in SC accumulation and poor systemic delivery.
- **Molecular Size Barrier:** Drugs with molecular weight exceeding 500 Da (the "500 Dalton rule") exhibit poor transdermal permeation due to steric exclusion by the SC lipid bilayers. Most clinically approved transdermal drugs have molecular weights below 400 Da, with estradiol (272 Da), fentanyl (337 Da), and nicotine (162 Da) being prime examples.
- **Metabolic Barrier:** The viable epidermis and dermis contain significant levels of phase I (CYP450) and phase II (glucuronosyltransferase, sulfotransferase) metabolizing enzymes that can biotransform drugs during permeation, reducing the bioavailability of metabolically susceptible drug candidates.
- **Immunological Barrier:** Langerhans cells—immunologically active dendritic cells residing in the viable epidermis—can recognize topically applied haptens and drug molecules as antigens, initiating sensitization reactions that manifest as allergic contact dermatitis upon repeated exposure.

Penetration Enhancers



Classification and Mechanisms of Penetration Enhancers Used in Transdermal Drug Delivery System.

Penetration enhancers—also termed chemical permeation enhancers (CPEs), sorption promoters, or accelerants—are substances that reversibly alter the barrier properties of the stratum corneum to increase the flux of a co-administered drug across the skin. An ideal penetration enhancer, as defined by Barry (1987) and elaborated by Jain (1997), should: be pharmacologically inert; be non-toxic, non-irritating, and non-allergenic; exert its effect reversibly with full recovery of SC barrier function upon removal; be cosmetically acceptable and odorless; be compatible with both drug and formulation excipients; and have a low cost and wide availability. In practice, no single chemical fully satisfies all these criteria, necessitating the use of combinations of enhancers that act synergistically by different mechanisms.

Chemical Penetration Enhancers

Solvents

Solvents constitute the most widely studied and utilized class of chemical penetration enhancers. Their primary mechanism involves solubilization of the SC lipids, increasing drug solubility within the SC, and disruption of the ordered lipid bilayer packing that constitutes the main diffusion barrier. Dimethyl sulfoxide (DMSO), the prototype chemical enhancer, acts by displacing water associated with SC proteins and lipids, creating hydrophilic pathways for drug permeation. Its clinical utility is, however, limited by its potent skin irritation, systemic absorption, and characteristic garlic-like odor. Ethanol—one of the most widely used pharmaceutical solvents—enhances transdermal flux by two mechanisms: extraction of intercellular lipids and fluidization of the lipid bilayer. It also acts as a co-solvent, increasing drug solubility in the donor compartment, thereby augmenting the concentration gradient driving diffusion. Propylene glycol (PG) is frequently used in combination with other enhancers and acts by altering the thermodynamic activity of the drug in the formulation.

Fatty Acids and Fatty Acid Esters

Long-chain unsaturated fatty acids, particularly oleic acid (C18:1), linoleic acid (C18:2), and linolenic acid (C18:3), are among the most potent and widely investigated penetration enhancers. Oleic acid acts by intercalating into the ordered lipid bilayers of the SC and creating permeable "pools" or liquid-crystalline phases within the otherwise gel-phase lipid matrix—a mechanism elegantly described using Fourier transform infrared spectroscopy (FTIR) studies published in the Journal of Controlled Release. At concentrations of 5–10% in propylene glycol, oleic acid has been shown to enhance the permeation of estradiol, piroxicam, and testosterone by 10–100-fold. Isopropyl myristate (IPM) and isopropyl palmitate are fatty acid esters that act primarily by increasing drug partitioning into the SC and reducing the viscosity of the lipid barrier.

Surfactants

Surfactants enhance transdermal permeation by disrupting the organized lipid architecture of the SC and extracting membrane proteins, creating defects in the barrier. Anionic surfactants such as sodium lauryl sulfate (SLS) are the most potent enhancers but cause significant skin irritation. Non-ionic surfactants—including polysorbates (Tween 20, 80), polyoxyl derivatives, and spans—are milder and preferred in pharmaceutical formulations. They act by solubilizing intercellular lipids and modifying protein conformation within the SC. Cationic surfactants (cetyltrimethylammonium bromide) and zwitterionic surfactants are also used but carry higher irritation potential. Optimized surfactant concentrations in formulations typically range from 0.5–2%.

Terpenes and Terpenoids

Naturally occurring terpenes and terpenoids represent a class of generally GRAS (Generally Recognized as Safe) penetration enhancers extracted from essential oils. Monoterpenes (menthol, camphor, limonene, cineole, thymol) are lipophilic cyclic compounds that enhance transdermal flux by disrupting SC lipid packing, increasing lipid fluidity, and in some cases acting as co-solvents. Menthol, the most extensively studied terpenoid, has demonstrated significant enhancement of estradiol, 5-fluorouracil, and indomethacin permeation in multiple published studies. Its pharmaceutical and sensory acceptability makes it a preferred option for commercial transdermal products. Azone (1-dodecylazacycloheptan-2-one)—a synthetic cyclic compound often classified with terpenes—is one of the most potent penetration enhancers known, operating at very low concentrations (0.1–1%) by selective partitioning into the intercellular SC lipids and disrupting their ordered packing.

Physical Penetration Enhancement Methods

Physical methods of enhancement offer the advantage of precise control over drug delivery rates without the biocompatibility concerns associated with chemical enhancers. Iontophoresis uses a small, continuous electrical current (typically 0.1–0.5 mA/cm²) to drive ionized drug molecules across the skin via electromigration (direct movement of charged drug molecules under the electric field) and electroosmosis (bulk fluid flow toward the cathode under applied electric field). Iontophoresis is particularly effective for ionic drugs, peptides, and proteins, with commercial applications including fentanyl iontophoretic patches (IONSYS) for postoperative pain management.

Sonophoresis (phonophoresis) employs therapeutic ultrasound (1–16 MHz, low-intensity: 0–2 W/cm²) to enhance skin permeability through a combination of thermal, mechanical (radiation pressure, microstreaming), and cavitational effects that reversibly disrupt SC lipid organization. Low-frequency sonophoresis (20–100 kHz) has demonstrated particularly impressive enhancement ratios for macromolecules including insulin and erythropoietin,

with potential applications in non-invasive systemic peptide delivery. Electroporation uses brief, high-voltage electrical pulses (50–100 µs, 100–1000 V/cm) to create transient aqueous pores in the SC lipid bilayers through which drugs diffuse. Unlike iontophoresis, electroporation is not limited to ionic drugs and can facilitate the transdermal delivery of neutral macromolecules.

Biochemical and Vesicular Enhancers

Vesicular drug delivery systems represent a sophisticated class of biochemical penetration enhancers. Transfersomes (ultradeformable liposomes) are elastic vesicles composed of phospholipids and edge activators (surfactants such as sodium deoxycholate) that exhibit extreme deformability, enabling them to squeeze through SC intercorneocyte channels much smaller than their own diameter. The osmotic gradient generated by the skin surface–dermis water activity difference provides the driving force for transfersome permeation. Ethosomes are phospholipid vesicles containing high concentrations of ethanol (20–45%) that act as penetration enhancers by disrupting SC lipid packing while simultaneously acting as fluidizing agents for the vesicle bilayer. Studies in the Journal of Controlled Release have demonstrated that ethosomal systems deliver drugs such as testosterone and cannabidiol to the dermis in quantities 10–100-fold higher than conventional formulations. Niosomes—non-ionic surfactant-based vesicles—and cubosomes have also been investigated as transdermal carriers with promising results.

Microneedle Systems

Microneedle (MN) arrays represent a minimally invasive physical approach to bypassing the stratum corneum barrier by creating transient microscale channels through the SC. Microneedles are arrays of solid, hollow, coated, or dissolving needles (25–800 µm in height, 1–25 µm tip diameter) fabricated from stainless steel, silicon, polymer (PLGA, PVP, PVA), or carbohydrates. Upon application to the skin, microneedles pierce the SC and upper epidermis without reaching the nerve-rich dermis, creating painless pores through which drugs permeate. Dissolving microneedles, incorporating drug within the needle matrix, offer the advantage of no sharps waste and complete drug delivery upon dissolution. Research published in Drug Development and Industrial Pharmacy has demonstrated that microneedle pretreatment increases the permeation of insulin 100-fold compared to passive delivery, with blood glucose levels controlled for over 6 hours in diabetic rat models.

Transdermal Drug Delivery Systems



Structural Design of Four Principal Types of Transdermal Drug Delivery Systems (Patches)

Transdermal Drug Delivery Systems encompass a broad range of dosage form designs, each exploiting different physicochemical principles to control drug release and skin permeation. The common structural elements of all transdermal patches include: a backing membrane (impermeable to drug); a drug-containing reservoir or matrix layer; a rate-controlling membrane (in some designs); a pressure-sensitive adhesive (PSA) layer; and a protective release liner removed prior to application. The choice of design is dictated by the physicochemical properties of the drug, the desired release kinetics, the target delivery site, and the duration of wear.

Membrane-Controlled Reservoir Systems

In membrane-controlled (reservoir) systems, the drug is contained in a liquid, semisolid, or solid reservoir separated from the skin by a rate-controlling polymeric membrane. The rate-controlling membrane—composed of microporous polypropylene (Celgard), ethylene-vinyl acetate copolymer (EVA), or polyurethane—determines the maximum drug flux to the skin and provides zero-order release kinetics by maintaining a constant concentration gradient across the membrane under sink conditions. The drug reservoir may contain the drug

dissolved or suspended in a biocompatible vehicle such as mineral oil, silicone fluid, or a gel matrix. A thin layer of PSA applied to the outer membrane surface adheres the patch to the skin surface.

The nitroglycerin transdermal system (Nitrodur, Transderm-Nitro) and the clonidine patch (Catapres-TTS) are classic examples of membrane-controlled reservoir systems. The flux of drug through the rate-controlling membrane (Jmem) is described by Fick's first law: Jmem = DmKm (Cd – Cr) / hm, where Dm is the diffusivity in the membrane, Km is the membrane/reservoir partition coefficient, Cd is the drug concentration in the reservoir, Cr is the drug concentration at the membrane–skin interface, and hm is the membrane thickness. The rate-controlling membrane ensures that membrane permeability (Pm = DmKm/hm) is the dominant resistance in the overall permeation system, independent of skin variability.

Matrix-Dispersion Systems

In matrix-dispersion systems, the drug is dissolved or dispersed uniformly throughout a polymeric matrix, which simultaneously controls drug release and provides adhesion to the skin surface. The drug-containing matrix—termed a monolithic system—is typically composed of hydrophilic polymers such as hydroxypropyl methylcellulose (HPMC), polyvinylpyrrolidone (PVP), or polyvinyl alcohol (PVA), or hydrophobic polymers such as ethyl cellulose, polyisobutylene (PIB), or polysiloxane. Drug release from matrix systems follows square-root-of-time (Higuchi) kinetics under sink conditions: Q = [D(2A − Cs)Cs·t]^0.5, where D is diffusivity in the matrix, A is initial drug loading, Cs is drug solubility in the matrix, and t is time.

Commercial examples of matrix TDDS include the Habitrol nicotine patch, diclofenac sodium patch (Flector Patch), and testosterone matrix patches (Androderm). Advantages over reservoir systems include lower risk of dose dumping upon membrane failure, simpler manufacturing, thinner and more flexible patch construction, and greater suitability for hydrophilic drugs. The drug loading in matrix patches must exceed the solubility (A > Cs) to maintain zero-order or near-zero-order release; below Cs, release transitions to first-order kinetics.

Drug-in-Adhesive Systems

Drug-in-adhesive (DIA) systems are the most commercially prevalent transdermal patch design, wherein the drug is directly dissolved or dispersed in the PSA layer, which concurrently functions as the drug reservoir and adhesive. This design eliminates the need for a separate rate-controlling membrane and drug reservoir, resulting in an ultra-thin, flexible, cosmetically elegant patch. PSAs used in DIA systems include acrylic copolymers, silicone PSAs, and PIB-based adhesives. The drug content in the PSA must be carefully optimized to avoid crystallization or phase separation, which can cause dose variability, and to prevent plasticization of the adhesive that would alter tack and adhesion properties.

Examples of commercial DIA patches include the fentanyl matrix patch (Durogesic DTrans), the rivastigmine patch (Exelon), the rotigotine patch (Neupro), and the buprenorphine patch (BuTrans). The primary advantage of DIA patches is their thinness (100–200 µm) and flexibility, which enhances patient wearability and adhesion conformity to body contours. Multilayer DIA patches—stacking two or more drug-loaded PSA layers with different drug concentrations or PSA compositions—can extend the wear period to 7 days while maintaining sustained drug delivery.

Microreservoir Systems

Microreservoir systems represent a hybrid design that combines the release kinetics of reservoir systems with the manufacturing simplicity of matrix systems. In these systems, the drug is first dissolved or suspended in a water-miscible solvent (e.g., polyethylene glycol, PEG) to form a drug concentrate, which is then dispersed as discrete, uniform microspheres (~100–600 µm diameter) within a lipophilic polymer matrix (polysiloxane or polyisobutylene) by high-shear mechanical dispersion. Each microsphere acts as an individual drug depot releasing drug by diffusion through the surrounding polymeric matrix. The testosterone transdermal system (Testoderm) is a notable example. The principal advantage of microreservoir systems is the absence of a macroscopic drug reservoir, eliminating the risk of accidental drug dose dumping.

Candidate Drugs for Transdermal Delivery

Drug	Therapeutic Category	MW (Da)	Log P
Estradiol	Hormone (HRT)	272	3.75
Nitroglycerin	Anti-anginal	227	0.62
Clonidine	Antihypertensive	230	1.57
Nicotine	Smoking cessation	162	1.17
Scopolamine	Anti-emetic	303	0.98
Testosterone	Hormone replacement	288	3.32
Diclofenac	Anti-inflammatory (NSAID)	296	4.40
Rivastigmine	Alzheimer's disease	250	2.21
Buprenorphine	Opioid analgesic	467	4.98

Physicochemical Properties of Selected Transdermal Drug Candidates

Formulation Of Transdermal Drug Delivery Systems

The formulation of an effective transdermal drug delivery system requires the meticulous selection and optimization of multiple components, each serving a specific functional role in the overall drug delivery performance. As summarized in Fig. 4 and elaborated below, the principal formulation components include the drug, polymer matrix, plasticizers, penetration enhancers, backing membrane, and pressure-sensitive adhesives. The interplay among these components determines the drug release rate, skin permeation flux, patch adhesion, flexibility, and patient acceptability.

Drug Selection and Physicochemical Optimization

The prerequisite for a successful transdermal formulation is a drug candidate with appropriate physicochemical properties. Based on the principles outlined by Vyas and Khar (2002) and Chien (1992), ideal transdermal drug candidates should have: (a) molecular weight below 500 Da; (b) a log P value between 1 and 4; (c) a melting point below 200°C; (d) a low daily therapeutic dose (below 20 mg/day); (e) adequate aqueous and lipid solubility; (f) a short biological half-life necessitating sustained systemic delivery; and (g) absence of skin-sensitizing properties. Drugs that cause skin irritation, are extensively metabolized in the skin, or have a very large volume of distribution are generally unsuitable for transdermal delivery.

The thermodynamic activity of the drug in the formulation is a critical parameter—drug flux across the skin is proportional to the thermodynamic activity (effective concentration) of the drug in the donor formulation rather than its absolute concentration. Supersaturated systems—where drug concentration exceeds solubility—exhibit enhanced thermodynamic activity and thus augmented transdermal flux. Supersaturation can be achieved by solvent evaporation, anti-solvent addition, or cooling from elevated temperatures, and is maintained by anti-nucleation agents such as HPMC or PVP that inhibit drug crystallization.

Polymers for Matrix Formation

Polymers constitute the structural backbone of matrix-type transdermal patches, controlling drug release rate, patch mechanical properties, and adhesion characteristics. Hydrophilic polymers commonly used in TDDS include HPMC (various viscosity grades: E5, K4M, K15M), polyvinyl pyrrolidone (PVP K30, K90), polyvinyl alcohol (PVA), and sodium carboxymethylcellulose (CMC). These polymers form hydrophilic matrices that swell on contact with skin moisture, releasing the drug by diffusion. Hydrophobic polymers including ethyl cellulose, cellulose acetate, polyacrylates (Eudragit RL100, RS100), and polyisobutylene (PIB) create lipophilic matrices favoring the permeation of hydrophilic drugs.

Natural polymers such as chitosan, sodium alginate, gelatin, and guar gum have also been investigated for matrix formation, offering biodegradability, good biocompatibility, and mucoadhesive properties. Blend matrices—combining hydrophilic and hydrophobic polymers in optimized ratios—allow fine-tuning of drug release kinetics to achieve the desired permeation profile. Solvent casting is the most common method of preparing polymer matrices for TDDS, wherein the drug, polymer(s), plasticizer, and penetration enhancer are dissolved in a common volatile solvent (ethanol, acetone, chloroform, or blends), poured onto a backing membrane, and dried under controlled conditions.

Plasticizers

Plasticizers are incorporated into transdermal formulations to improve the flexibility, mechanical strength, and processability of the polymer matrix by reducing the glass transition temperature (Tg) of the polymer and increasing free volume within the matrix. Without adequate plasticization, polymer films are brittle and prone to cracking during handling and wear. Polyethylene glycols (PEG 200, 400, 600) are the most widely used hydrophilic plasticizers, acting by interposing their flexible molecular chains between polymer chains and weakening intermolecular interactions. Dibutyl phthalate (DBP), triethyl citrate (TEC), dioctyl phthalate, and castor oil serve as hydrophobic plasticizers. Propylene glycol provides dual functionality as both a plasticizer and a penetration enhancer in many formulations. Typical plasticizer concentrations range from 10–30% w/w of the polymer.

Pressure-Sensitive Adhesives (PSA)

PSAs are critical functional excipients that provide and maintain intimate contact between the transdermal patch and the skin surface throughout the intended wear period. An ideal PSA for TDDS must demonstrate: sufficient adhesion to attach firmly to skin without mechanical aids; adequate cohesive strength to leave no residue upon removal; compatibility with the drug and other formulation components; absence of skin sensitization potential; and stability under the temperature and humidity conditions of storage and use. The three principal classes of PSAs used in commercial transdermal products are: acrylic PSAs (cross-linked acrylate copolymers, e.g., Duro-Tak series by Henkel), which offer excellent compatibility with most drugs, transparency, and good release liner anchorage; silicone PSAs, which provide good adhesion to compromised or hairy skin and excellent biocompatibility; and PIB-based PSAs, which are hydrophobic and preferred for moisture-sensitive formulations.

Backing Membranes and Release Liners

The backing membrane serves as the outer surface of the transdermal patch, providing mechanical support, impermeability to drug (preventing drug loss from the outer surface), and a moisture barrier. Common backing materials include polyester films (Melinex, Scotchpak

9723), polyurethane foams, polypropylene, and metallized foil laminates. The choice of backing material affects patch flexibility, occlusive properties, moisture vapor transmission rate (MVTR), and patient skin response. Occlusive backing membranes (low MVTR) increase skin hydration under the patch, potentially enhancing drug permeation but also increasing the risk of skin maceration. The release liner—a silicone-coated or fluoropolymer-coated film removed before application—protects the adhesive surface during storage and must be cleanly peelable without causing adhesive transfer.

Preparation Methods for Transdermal Patches

- **Solvent Casting Method:** The drug, polymer, plasticizer, and penetration enhancer are dissolved in a common volatile solvent system. The solution is cast onto a backing membrane using a film applicator, dried at controlled temperature (40–60°C) for 12–24 hours, and the dried film is laminated with a release liner. This is the most common and scalable preparation method.
- **Hot Melt Extrusion:** Drug and polymers are processed in the molten state using a twin-screw extruder, enabling solvent-free production of drug-polymer matrices with enhanced drug-polymer miscibility. Suitable for thermally stable drugs.
- **Membrane Lamination:** For reservoir patches, the drug reservoir (liquid or semisolid) is enclosed between the backing membrane and the rate-controlling membrane using heat or ultrasonic sealing, followed by application of the PSA layer and release liner.
- **Microsphere Suspension Casting:** For microreservoir systems, drug-loaded microspheres are prepared and dispersed in the polymer matrix solution prior to casting, producing patches with discrete drug-containing domains.

Evaluation of Transdermal Drug Delivery Systems

The evaluation of transdermal drug delivery systems encompasses a comprehensive battery of physicochemical, in vitro, ex vivo, and in vivo tests, as illustrated in Fig. 5. These tests assess the physical integrity, drug content, mechanical properties, drug release kinetics, skin permeation characteristics, safety, and in vivo pharmacokinetic performance of the transdermal formulation. Regulatory guidelines from the ICH, FDA, and CDSCO require comprehensive characterization across all these domains before clinical evaluation.

Physicochemical Evaluation

Thickness uniformity is determined by measuring the patch thickness at multiple points (center and four quadrants) using a calibrated dial gauge or digital micrometer. A coefficient of variation (CV) below 2% indicates acceptable uniformity. Weight variation is assessed by weighing 10 patches on an analytical balance; acceptable limits require no individual patch to deviate more than ±5% from the mean. Folding endurance—a measure of mechanical strength—is determined by repeatedly folding the patch at the same location and recording the number of folds before the film cracks; a minimum of 300 folds without cracking is generally required.

Moisture content is assessed by weighing patches before and after drying in a desiccator over anhydrous calcium chloride for 24 hours. Optimal moisture content (2–10% w/w) is required to prevent brittleness (too dry) or excessive tackiness (too moist). Moisture uptake studies assess dimensional stability and drug stability under high humidity conditions (40°C/75% RH, ICH Zone IVb conditions). Drug content uniformity is determined by dissolving a defined area of the patch (typically 1 cm^2) in an appropriate solvent and assaying by HPLC or UV spectrophotometry; acceptance criteria require RSD below 2% across 10 patches.

***In Vitro* Drug Release Studies**

In vitro drug release from transdermal patches is assessed using USP Apparatus V (paddle-over-disk method), Apparatus VI (rotating cylinder or rod method), or Franz diffusion cells with a synthetic membrane (regenerated cellulose, polysulfone, or silicone). The patch or drug-loaded membrane is mounted on the apparatus, and cumulative drug release into the dissolution medium (pH 7.4 phosphate buffer or simulated skin fluid) is measured at specified time intervals by HPLC or UV spectrophotometry. Release data are analyzed using zero-order, first-order, and Higuchi models, and the Korsmeyer-Peppas model ($Q/Q\infty = k \cdot t^n$) to determine the release mechanism; $n = 0.5$ indicates Fickian diffusion, $0.5 < n < 1$ indicates anomalous transport, and $n \geq 1$ indicates Case II (erosion-controlled) transport.

***Ex Vivo* Skin Permeation Studies (Franz Diffusion Cell)**

Franz diffusion cell studies using excised skin constitute the gold standard for ex vivo evaluation of transdermal flux. Full-thickness or dermatomed human cadaver skin, rat skin, rabbit skin, pig ear skin, or snake skin (shedded epidermis) is mounted between the donor and receptor compartments of a Franz diffusion cell (effective diffusion area: 0.636–1.767 cm^2). The receptor compartment contains the receptor fluid (phosphate buffer pH 7.4 with 20% ethanol or an appropriate co-solvent to maintain sink conditions), maintained at 32°C (skin surface temperature) and continuously stirred. Samples are withdrawn at defined intervals (1, 2, 4, 6, 8, 12, 24 h) and replaced with fresh receptor fluid, then assayed by HPLC.

The steady-state flux (Jss, µg/cm^2/h) is calculated as the slope of the linear portion of the cumulative permeation versus time plot. The permeability coefficient (Kp) is determined as Jss/Cv, where Cv is the donor concentration. The lag time (tlag) is determined by extrapolating the linear portion of the permeation curve to the time axis. Drug diffusivity (D) and SC-vehicle

partition coefficient (K) can be extracted from Jss, Kp, and tlag values using membrane transport equations. Confocal laser scanning microscopy (CLSM) and tape-stripping studies are used to visualize and quantify drug penetration depth within the SC and viable epidermis.

Rheological and Adhesion Tests

For adhesive patches, the following mechanical tests are conducted: Peel adhesion (90° or 180° peel test) measures the force required to remove the patch from the substrate (stainless steel or polyethylene panel) using a texture analyzer, providing a measure of adhesive bond strength. Tack (quick-stick or probe tack) measures the force required to rapidly separate a probe from the adhesive surface, characterizing initial adhesion. Shear resistance (static shear or dynamic mechanical analysis) measures resistance to lateral displacement under constant load, providing a measure of cohesive strength critical for patch integrity during wear. Skin occlusion factor and moisture vapor transmission rate (MVTR) are measured gravimetrically and determine the extent of skin hydration under the patch.

Stability Studies

Transdermal patches are subjected to accelerated and long-term stability studies as per ICH Q1A(R2) guidelines. Accelerated studies are conducted at 40°C/75% RH for 6 months, while real-time stability studies are conducted at 25°C/60% RH for 24 months (Zone I/II) or 30°C/65% RH for 12 months (Zone III/IVa). Evaluation parameters include physical appearance, drug content, drug release rate, adhesion properties, and—for patches incorporating penetration enhancers—analysis of degradation products and changes in viscosity or consistency. Photostability testing (ICH Q1B) is required for patches containing photolabile drugs or excipients.

***In Vivo* Studies and Bioavailability Assessment**

Animal models including hairless mice (SKH-1 strain), Wistar rats, New Zealand white rabbits, miniature pigs, and beagle dogs are used for preclinical in vivo evaluation of TDDS. The patch is applied to a shaved skin site, and serial blood samples are collected at defined intervals for pharmacokinetic analysis. Key parameters assessed include plasma concentration–time profiles, AUC (area under the curve), Cmax (peak concentration), Tmax (time to peak), and bioavailability relative to oral or parenteral administration. Gamma scintigraphy using radiolabeled patches (^{99}mTc) enables non-invasive visualization of patch adherence, skin hydration patterns, and drug distribution.

Dermatopharmacokinetic (DPK) studies—quantifying drug amounts in tape-strip samples from the stratum corneum at defined time points—provide a rapid, non-invasive surrogate for skin permeation and are increasingly accepted by regulatory bodies as an in vivo bioequivalence methodology for topical and transdermal generics.

Clinical Applications of Transdermal Drug Delivery

- **Cardiovascular Diseases:** Nitroglycerin (Nitrodur), clonidine (Catapres-TTS), and isosorbide dinitrate transdermal systems provide continuous prophylactic management of angina pectoris and hypertension, eliminating tolerance that develops with oral or sublingual administration through intermittent (patch-free period) dosing strategies.
- **Pain Management:** Fentanyl (Durogesic), buprenorphine (BuTrans), diclofenac (Flector), and lidocaine patches provide around-the-clock analgesia for chronic pain conditions, cancer pain, and postoperative pain without the adverse GI effects of oral opioids and NSAIDs.
- **Hormone Replacement Therapy:** Estradiol, estradiol-norethindrone combination (CombiPatch), and testosterone patches (Androderm, Testoderm) provide steady-state hormone levels mimicking physiological patterns, improving tolerability compared to oral hormones subject to hepatic first-pass.
- **Neurological Disorders:** Rotigotine (Neupro) and rivastigmine (Exelon) patches provide continuous dopaminergic stimulation for Parkinson's disease and steady cholinesterase inhibition for Alzheimer's dementia, reducing adverse effects associated with peak oral drug levels.
- **Smoking Cessation:** Nicotine transdermal systems (Nicoderm CQ, Nicorette CQ) deliver controlled nicotine doses to manage withdrawal symptoms, with significant improvements in abstinence rates compared to unaided cessation.
- **Contraception:** The norelgestromin/ethinyl estradiol patch (Ortho Evra) provides weekly hormonal contraception with bioavailability and efficacy comparable to combined oral contraceptive pills, with improved compliance through once-weekly dosing.

CONCLUSION

Transdermal drug delivery systems have established themselves as a clinically valuable and commercially significant drug delivery platform, offering unique pharmacokinetic advantages that complement and, in many respects, surpass the capabilities of conventional oral and parenteral dosage forms. The ability to deliver drugs continuously at controlled rates, bypass hepatic first-pass metabolism, avoid gastrointestinal degradation, minimize peak-trough plasma concentration fluctuations, and enable patient-controlled therapy initiation and termination—by simply applying or removing the patch—represents an unmatched combination of clinical and patient-compliance benefits.

The fundamental understanding of skin structure—particularly the stratum corneum brick-and-mortar lipid architecture and its role as the principal barrier to transdermal drug permeation—has enabled the rational design of penetration enhancement strategies that range

from chemical solvent systems and fatty acids to sophisticated physical technologies such as iontophoresis, sonophoresis, electroporation, and microneedle arrays. The evolution from simple reservoir membrane patches to matrix-dispersion systems, drug-in-adhesive patches, and microreservoir designs has expanded the candidate drug space and improved product aesthetics and wearability.

The formulation of transdermal patches demands the harmonious optimization of drug physicochemical properties, polymer matrix selection, plasticizer incorporation, penetration enhancer choice, PSA performance, and backing membrane characteristics—all within the constraints of skin biocompatibility and product stability. The evaluation framework—spanning physicochemical characterization, in vitro drug release, Franz diffusion cell permeation studies, adhesion testing, stability assessment, and in vivo pharmacokinetic profiling—provides a robust scientific basis for product development and regulatory approval.

Looking forward, the integration of nanotechnology (nanoparticles, transfersomes, ethosomes, lipid nanocarriers), dissolving and coated microneedle arrays, smart responsive hydrogels, and wearable biosensor-coupled feedback systems promises to dramatically expand the range of therapeutics deliverable via the transdermal route, including peptides, proteins, nucleic acids, and vaccines. The transdermal field stands at the confluence of materials science, biotechnology, pharmacokinetics, and clinical medicine—continuing to evolve as a frontier of innovation in drug delivery science.

REFERENCES

1. Chien YW. Novel Drug Delivery Systems. 2nd edition, revised and expanded. Marcel Dekker, Inc., New York, 1992.
2. Robinson JR, Lee VHL. Controlled Drug Delivery Systems. Marcel Dekker, Inc., New York, 1992.
3. Mathiowitz E (Ed.). Encyclopedia of Controlled Delivery. Wiley-Interscience Publication, John Wiley and Sons, Inc., New York/Chichester/Weinheim, 1999.
4. Jain NK. Controlled and Novel Drug Delivery. CBS Publishers & Distributors, New Delhi, First Edition, 1997 (Reprint 2001).
5. Vyas SP, Khar RK. Controlled Drug Delivery: Concepts and Advances. Vallabh Prakashan, New Delhi, First Edition; 2002.
6. Prausnitz MR, Langer R. Transdermal drug delivery. Nature Biotechnology, 2008; 26(11): 1261–1268.
7. Benson HAE. Transdermal drug delivery: penetration enhancement techniques. Current Drug Delivery, 2005; 2(1): 23–33.
8. Williams AC, Barry BW. Penetration enhancers. Advanced Drug Delivery Reviews, 2004; 56(5): 603–618.
9. Trommer H, Neubert RHH. Overcoming the stratum corneum: the modulation of skin penetration. Skin Pharmacology and Physiology, 2006; 19(2): 106–121.
10. Naik A, Kalia YN, Guy RH. Transdermal drug delivery: overcoming the skin's barrier function. Pharmaceutical Science and Technology Today, 2000; 3(9): 318–326.
11. Paudel KS, Milewski M, Swadley CL, Brogden NK, Ghosh P, Stinchcomb AL. Challenges and opportunities in dermal/transdermal delivery. Therapeutic Delivery, 2010; 1(1): 109–131.
12. Nair AB, Al-Dhubiab BE, Shah J, Jacob S, Attimarad M, Alnahdi SA. Transdermal drug delivery of pharmaceuticals: trends and challenges. Journal of Drug Delivery Science and Technology. 2022; 68:103–112.
13. Tekade RK. Basic Fundamentals of Drug Delivery. Academic Press, 2019.
14. Subramani K, Ahmed W (Eds.). Emerging Nanotechnologies for Diagnostics, Drug Delivery and Medical Devices. Elsevier, 2017.
15. Wiedersberg S, Guy RH. Transdermal drug delivery: 30+ years of war and still fighting. Journal of Controlled Release, 2014; 190: 150–156.
16. Pham QD, Björklund S, Engblom J, Topgaard D, Sparr E. Chemical penetration enhancers in stratum corneum – Relation between molecular effects and barrier function. Journal of Controlled Release, 2016; 232: 175–187.